TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07665723: A Phase I, Multicenter, Open-Label, Single-Agent Study to Assess the Pharmacokinetics of Cytochrome P450 Substrates After Treatment With Afimkibart in Participants With Moderately to Severely Active Ulcerative Colitis

Sponsor: Hoffmann-La Roche · Phase: PHASE1 · Area: IMMUNOLOGY · Target Enrollment: 25 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$281,520

Rescue Site Savings

+$187,680

Unlock Full NCT07665723 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07665723 Rescue Dossier →